$MYOV Myovant announced positive Phase 3 SPIRIT 2 data of QD relugolix combo therapy (relugolix 40mg + estradiol 1.0mg + norethindrone acetate 0.5mg) in women with pain associated with endometriosis.

Met co-primary endpoints and 6/7 key secondaries. https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-positive-results-phase-3-spirit-2

Nice thread on how these $MYOV Phase 3 SPIRIT 2 data with QD relugolix compare to $ABBV / $NBIX Phase 3 ELARIS data with QD/BID elagolix data in #endometriosis.

Relevant to $OBSV as well.

https://twitter.com/biopharma_cg/status/1252933191066947586?s=21 https://twitter.com/biopharma_cg/status/1252933191066947586